Survival Among Patients With Pancreatic Cancer Depending on Surgical Resection Rate

Survival Among Elderly Patients in Sweden With Right-sided Pancreatic Adenocarcinoma Depending on Resection Rate of Pancreaticoduodenectomy

The primary aim of this population-based study is to investigate how a high resection rate of pancreaticoduodenectomy affects overall survival among patients aged ≥70 years with pancreatic ductal adenocarcinoma. The secondary aim is to determine if a high resection rate of pancreaticoduodenectomy increases perioperative morbidity.

Study Overview

• Status: Completed
• Conditions: Pancreatic Ductal Adenocarcinoma
• Intervention / Treatment: Other: Resection rates

• Study Type: Observational
• Enrollment (Actual): 5123

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

All patients registered in the Swedish National Registry for tumours in the pancreatic and periampullary region diagnosed with right-sided pancreatic adenocarcinoma or resected with pancreaticoduodenectomy

Description

Inclusion Criteria:

• Diagnosed between 1 January 2010 and 31 December 2018
• Registered in the Swedish National Registry for tumours in the pancreatic and periampullary region
• Either a diagnosis of pancreatic ductal adenocarcinoma of the pancreatic head or having been resected with pancreaticoduodenectomy

Exclusion Criteria:

• None

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Other

Number of groups / cohorts

6

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
All patients with pancreatic ductal adenocarcinoma aged 70 years and older; All patients in the registry aged 70 years and older with right-sided pancreatic ductal adenocarcinoma	Other: Resection rates; All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
All patients with pancreatic ductal adenocarcinoma aged 70-79 years; All patients in the registry aged 70-79 years with right-sided pancreatic ductal adenocarcinoma	Other: Resection rates; All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
All patients with pancreatic ductal adenocarcinoma aged 80 years and older; All patients in the registry aged 80 years and older with right-sided pancreatic ductal adenocarcinoma	Other: Resection rates; All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
All patients resected with pancreaticoduodenectomy, all ages; All patients in the registry resected with pancreaticoduodenectomy during the study period	Other: Resection rates; All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
All patients resected with pancreaticoduodenectomy, aged 70-79 years; All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 70-79 years	Other: Resection rates; All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)
All patients resected with pancreaticoduodenectomy, aged 80 years and older; All patients in the registry resected with pancreaticoduodenectomy during the study period, aged 80 years and older	Other: Resection rates; All groups are divided into one high- and one low resection rate group depending on percentage of patients with pancreatic ductal adenocarcinoma resected per county and year (first three groups) and resection rate of pancreaticoduodenectomy per 100 000 inhabitants per county (last three groups)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	Overall survival among patients aged 70 years and over with pancreatic ductal adenocarcinoma in the pancreatic head	A little more than 10 years (from first patient to vital status)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Severe complications after pancreaticoduodenectomy	The rate of severe complications among patients aged 70 years and over who had undergone pancreaticoduodenectomy for any reason	Around 10 years (patients diagnosed between 1 January 2010 and 31 December 2018, latest dismissal from hospital january 2020)

Collaborators and Investigators

• Sponsor: Linkoeping University

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2010
• Primary Completion (Actual): October 2, 2020
• Study Completion (Actual): October 2, 2020

Study Registration Dates

• First Submitted: March 15, 2021
• First Submitted That Met QC Criteria: March 15, 2021
• First Posted (Actual): March 17, 2021

Study Record Updates

• Last Update Posted (Actual): March 17, 2021
• Last Update Submitted That Met QC Criteria: March 15, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: pancreaticoduodenectomy
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Adenocarcinoma
• Other Study ID Numbers: 2017/151-31

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: The data cannot be further shared by the researchers but is available on application to the Swedish National Registry for tumours in the pancreatic and periampullary region, provided the application is approved by the Swedish Ethical Review Authority

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No